Modality
Degrader
MOA
Anti-Tau
Target
PSMA
Pathway
T-cell
MigraineLGSParkinson's
Development Pipeline
Preclinical
Oct 2017
→ Feb 2027
PreclinicalCurrent
NCT05473336
1,782 pts·Migraine
2022-09→2025-01·Not yet recruiting
NCT07165616
636 pts·LGS
2017-10→2027-02·Active
2,418 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-01-141.2y agoInterim· Migraine
2027-02-1310mo awayInterim· LGS
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
Preclinical
Active
Preclinical
Not yet…
Catalysts
Interim
2025-01-14 · 1.2y ago
Migraine
Interim
2027-02-13 · 10mo away
LGS
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05473336 | Preclinical | Migraine | Not yet recr... | 1782 | PASI75 |
| NCT07165616 | Preclinical | LGS | Active | 636 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| BGN-3859 | BeiGene | Approved | PSMA |